Skip to main content
SAREUM HOLDINGS PLC logo

SAREUM HOLDINGS PLC — Investor Relations & Filings

Ticker · SAR ISIN · GB00BMC3RJ87 LEI · 213800PKERN2DY8FFM72 IL Manufacturing
Open in API
Filings indexed 348 across all filing types
Latest filing 2023-08-03 Share Issue/Capital Cha…
Country GB United Kingdom
Listing IL SAR

About SAREUM HOLDINGS PLC

https://www.sareum.com/

Sareum Holdings PLC is a clinical-stage small molecule company that discovers and develops next-generation kinase inhibitors for the treatment of autoimmune diseases and cancer. The company's research is primarily focused on the TYK/JAK kinase cell signalling family, with a specific emphasis on developing dual inhibitors of TYK2 and JAK1. This approach is pursued for its potential to offer superior efficacy compared to agents that target only one of these kinases. Its development pipeline includes SDC-1801, a potential oral therapy for autoimmune diseases, as well as other programs targeting cancer and viral infections.

Recent filings

Filing Released Lang Actions
Equity Prepayment Facility of up to £5 million
Share Issue/Capital Change Classification · 99% confidence The document is a formal announcement dated August 3, 2023, originating from Sareum Holdings PLC, identified by the RNS Number 1392I. The content details the agreement of an 'Equity Prepayment Facility of up to £5 million' with RiverFort, including specifics on deposits, share issuance, warrants, and the intended use of funds for clinical development (SDC-1801). This type of announcement, detailing significant financing activities, capital structure changes, and regulatory compliance (MAR disclosure), strongly aligns with the definition of a Capital/Financing Update (CAP). Although the document mentions an investor presentation link, the primary focus and substance are the financing terms, making CAP a more specific classification than RPA or RNS. The document is substantial (15,993 chars), indicating it is the primary announcement, not just a brief notice of publication.
2023-08-03 English
Sareum Announces Two New Granted Patents
Regulatory Filings Classification · 99% confidence The document is a formal announcement released via the RNS (Regulatory News Service) system, indicated by the 'RNS Number' and the closing footer referencing RNS and the London Stock Exchange. The content details the granting of new patents for the company's drug candidates (SDC-1801 and SDC-1802), which relates to intellectual property and R&D progress. This type of announcement, which is a specific corporate update not covered by the more specific categories like ER, DIV, or DIRS, fits best under the general 'Regulatory Filings' category (RNS) as a miscellaneous regulatory announcement, or potentially 'IP' (Intellectual Property). Given the context of RNS being the distribution mechanism and the content being a general corporate update about IP, RNS is the most appropriate general classification for this type of filing when IP is not explicitly listed as a primary code, although IP is listed. Since the document is a direct announcement of an event (patent grant) rather than a presentation (IP) or a report announcement (RPA), and it is distributed via RNS, RNS serves as the appropriate catch-all for significant, non-standard regulatory news. However, since 'IP' (Intellectual Property) is an available code, and the core subject is patent grants, 'IP' is a stronger fit than the general 'RNS' fallback. I will classify it as IP.
2023-06-26 English
Dosing commences in Phase 1a trial of SDC-801
Legal Proceedings Report Classification · 99% confidence The document begins with an 'RNS Number' and is dated '06 June 2023'. It announces a specific corporate event: 'Sareum announces dosing of first subjects in Phase 1a clinical trial for SDC-1801'. This is a time-sensitive, material update regarding clinical trial progress, which is typically disseminated via regulatory news services. The presence of the RNS header and the nature of the announcement (clinical trial update) strongly suggest this is a general regulatory announcement rather than a comprehensive report (like 10-K or IR) or a specific management/governance filing. Since it is a general regulatory announcement that doesn't fit perfectly into the other specific categories (like DIV, DIRS, or ER), the most appropriate classification is the general regulatory filing category.
2023-06-06 English
Phase 1a clinical trial for SDC-1801
Regulatory Filings Classification · 99% confidence The document begins with 'RNS Number : 8615Z' and contains standard regulatory boilerplate language at the end, including references to RNS, the London Stock Exchange, and the Financial Conduct Authority (FCA). This strongly indicates a regulatory announcement disseminated via the RNS system. The content itself announces the commencement of a Phase 1a clinical trial for a drug candidate (SDC-1801). This type of operational/clinical update, when released via RNS and not fitting into specific categories like Director's Dealing (DIRS), Earnings Release (ER), or Capital Change (CAP), defaults to the general regulatory filing category. Given the document's nature as a formal announcement distributed through the RNS system, the most appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement that doesn't map perfectly to the more specific operational/financial codes.
2023-05-18 English
Approval to initiate Phase 1 clinical trial
Regulatory Filings Classification · 100% confidence The document is identified by the 'RNS Number' header and contains a date (05 May 2023) and company information, typical of a regulatory news service announcement. The content announces the approval to initiate a Phase 1 clinical trial for a product (SDC-1801) and includes commentary from the CEO. This is a specific corporate update regarding clinical progress, which is not covered by the more specific categories like 10-K, ER, or IR. Since it is a formal announcement distributed via RNS (London Stock Exchange's news service) and deals with operational/clinical progress rather than a major financial filing, the most appropriate general category for such a regulatory news release that doesn't fit elsewhere is 'Regulatory Filings' (RNS). It is not a Report Publication Announcement (RPA) because it contains substantive news, not just a notice that a report is available.
2023-05-05 English
Half-Year Report
Interim / Quarterly Report Classification · 100% confidence The document is a 'Half-Year Report' for Sareum Holdings PLC for the period ended 31 December 2022. It contains substantive financial data (cash position, loss on ordinary activities, R&D tax credits) and detailed management analysis of operational activities, pipeline progress, and future outlook. It is not a mere announcement of a report (RPA) nor a simple regulatory filing (RNS), as it provides the actual financial and operational content for the interim period. Therefore, it is classified as an Interim / Quarterly Report. H1 2022
2023-03-22 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.